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Compound A (CpdA), a dissociated glucocorticoid receptor
modulator, decreases corticosteroid-binding globulin (CBG),
adrenocorticotropic hormone (ACTH), and luteneinizing
hormone levels in rats. Whether this is due to transcriptional
regulation by CpdA is not known. Using promoter reporter
assays we show that CpdA, like dexamethasone (Dex), di-
rectly transrepresses these genes. Results using a rat Cbg
proximal-promoter reporter construct in BWTG3 and
HepG2 cell lines support a glucocorticoid receptor (GR)-de-
pendent transrepression mechanism for CpdA. However,
CpdA, unlike Dex, does not result in transactivation via
glucocorticoid-responsive elements within a promoter
reporter construct even when GR is co-transfected. The
inability of CpdA to result in transactivation via glucocorti-
coid-responsive elements is confirmed on the endogenous
tyrosine aminotransferase gene, whereas transrepression
ability is confirmed on the endogenous CBG gene. Consistent
with a role for CpdA in modulating GR activity, whole cell
binding assays revealed that CpdA binds reversibly to the GR,
but with lower affinity thanDex, and influences association of
[3H]Dex, but has no effect on dissociation. In addition, like
Dex, CpdA causes nuclear translocation of the GR, albeit to a
lesser degree. Several lines of evidence, including fluores-
cence resonance energy transfer, co-immunoprecipitation,
and nuclear immunofluorescence studies of nuclear localiza-
tion-deficient GR show that CpdA, unlike Dex, does not elicit
ligand-induced GR dimerization. Comparison of the behav-
ior of CpdA in the presence of wild type GR to that of Dex with
a dimerization-deficient GR mutant (GRdim) strongly sup-
ports the conclusion that loss of dimerization is responsible
for the dissociated behavior of CpdA.
CpdA4 is a more stable analogue of the labile compound
found in the Namibian plant, Salsola tuberculatiformis
Botschantzev, which causes prolonged gestation in sheep and
contraception in rats (1). CpdA, like the shrub, causes contra-
ception in rats (2). Further investigation at amolecular level has
shown that CpdA competitively inhibits sheep adrenal cyto-
chrome P450-dependent steroid 11-hydroxylase (P450c11),
the enzyme responsible for the final step in the synthesis of
glucocorticoids (GCs) (2, 3). In addition, CpdA binds to and
displaces endogenousGCs from rat and sheepCBG, the plasma
globulin that binds GCs with high affinity (4). Studies inWistar
rats suggest that the latter mechanism predominates in vivo
with significantly increased free corticosterone levels due to
displacement from CBG by CpdA and concomitant decreases
in CBG, ACTH, and LH levels (5). Although the significant
decreases in CBG, ACTH, and LH levels may be ascribed solely
to feedback regulation mediated by the increase in a free, bio-
logically active GC concentration, it was postulated that direct
interaction of CpdA with the GR should not be discounted (5).
The fact thatCpdA interactswith the twoGC-binding proteins,
P450c11 and CBG, implies that interaction and signaling
through theGRmay be a distinct possibility. Indeed, our recent
article (6) describes such an interaction within the context of
anti-inflammatory action.
TheGR is a ligand-dependent transcription factormediating
the effects of GCs (7). In the absence of ligand, the GR is pre-
dominantly cytoplasmic. Upon ligand binding the GR translo-
cates to the nucleus, where the activated receptor can transac-
tivate or transrepress specific genes (8). Several models for
transcriptional modulation by the GR have been presented
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(9–11). Broadly speaking, transactivation is mediated by bind-
ing of a GR dimer to glucocorticoid response elements (GREs)
in the promoter region of GC-responsive genes, followed by
recruitment of coactivators, chromatin remodeling, and in-
creased gene transcription (12). Although transrepression may
also be mediated via direct binding to DNA, via negative GREs
(9), it mostly proceeds, without direct DNA binding by the GR,
via protein-protein interactions that require binding of the GR
monomer to other transcription factors, such as NFB, AP-1,
and C/EBP (10, 13–16). This last mechanism is often called
tethering.
The current study establishes that CpdA, like Dex, directly
transrepresses the three genes, Cbg, proopiomelanocortin
(Pomc), and gonadotropin-releasing hormone (Gnrh),
shown to be involved in the in vivo response to CpdA and
that these results are thus not only due to the increase in free
corticosterone (5). Further investigation indicates that
CpdA transrepression of Cbg is GR-mediated. Despite its
ability to transrepress GC-sensitive genes, CpdA is unable to
transactivate GRE-containing promoters. Analysis of the
molecular mechanism of action of CpdA via the GR indicates
that CpdA binds reversibly to endogenous rat GR, influences
association but not dissociation of [3H]Dex, and causes
nuclear translocation of liganded GR, although to a lesser extent
than Dex. However, CpdA, unlike Dex, does not result in dimer-
ization of the GR. The implications of loss of dimerization are
explored further by comparing the activity of CpdA via the wtGR
with that of Dex via a dimerization-deficient GR mutant (GRdim)
(16). Nuclear translocation behavior and transrepression medi-
ated by CpdA via the wtGR does not differ significantly from that
observed with Dex via the GRdim strongly supporting a mecha-
nismwhereby the inabilityofCpdAtoelicit ligand-induceddimer-
ization of the GR is responsible for its dissociated behavior.
EXPERIMENTAL PROCEDURES
Test Compounds—Dex, phorbol 12-myristate 13-acetate
(PMA), aldosterone, 4,5-dihydrotestosterone (DHT), 17-es-
tradiol (E2), spironolactone, and mifepristone (RU486) were
obtained from Sigma, ICI 182,780 from Tocris, R5020 from
PerkinElmer Life Sciences, and hydroxyflutamide was a kind
gift from Dr. C. Tendler (Schering Plough Research Institute).
Compound A (CpdA; 2-(4-acetoxyphenyl)-2-chloro-N-meth-
ylethylammonium chloride) was synthesized as described pre-
viously (2).
Plasmids—G. L. Hammond kindly provided the rat Cbg
proximal promoter reporter construct (rCBG295Luc) (17). The
Gnrh promoter reporter construct (3446mGnRHluc) was
donated by D. DeFranco (18). The rat Pomc promoter reporter
construct (JA300) and the expression vector for NUR77
(pCMX-Nur77) were gifts from J. Drouin (19). The -galacto-
sidase reporter plasmid (pPGKGeopbA) was a gift from P.
Soriano (Fred Hutchinson Cancer Research Centre, Seattle,
WA) and the pGL2-basic empty vector was obtained from Pro-
mega. The rat GR (pSVGR1) expression vector was a gift from
R. Miesfield (20), whereas the human GR (pRS-hGR) and
human MR (pRS-hMR) were gifts from R. M. Evans (Howard
Hughes Medical Institute, La Jolla, CA). CFP-tagged GR
(pECFP-hGR) and YFP-tagged GR (pEYFP-hGR) were gifts
from J. Cidlowski (21). Mouse wtGR (pcDNA3.1-GRWT) and
the mouse GRdim (pcDNA3.1-GRdim) mutant were gifts from
H. Reichardt (22). Rat GR (pTC2-wtGRrat) and c-myc-tagged
nuclear translocation mutant GR (myGRNL1) were gifts from
R. Hache´ (23). Human ER (pcDNA3-ER) was a gift from D.
Harnish (24). Human PRB (pSG5hPRB) was obtained from S.
Simons Jr. (25) and humanAR (pSVARo) was obtained fromA.
Brinkmann (26). (GRE)250hIL6PLuc and the FLAG-tagged GR
pEFFlaghGR (molecular mass, 96 kDa) were constructed as
previously described (27, 28), whereas the (GRE)2tkLuc con-
struct, and GFP-tagged GR (pEGFP-C2-GR, molecular mass,
128.5 kDa) were provided by S. Okret (Dept. of Medical Nutri-
tion, Karolinska Institute, Sweden). The GRE-containing pro-
moter reporter construct (pTAT-GRE2-Elb-luc)was a gift from
G. Jenster (29), the ERE-containing promoter reporter con-
struct (pGL2–3x-ERE-TATA-luc) was from D. McDonnell
(30), whereas the IL6-luc promoter reporter construct
(p(IL6B)350hu.IL6Pluc) has been described previously (31).
Cell Culture—BWTG3 (LEGEST, University of Gent, Bel-
gium), HepG2 (Highveld Biological Association, South Africa),
and COS-1 cells (ATCC) were cultured in high glucose (4.5
g/ml) Dulbecco’s modified Eagle’s medium (DMEM) (Sigma)
supplemented with 10% FCS (Highveld Biologicals, South
Africa), 100 IU/ml of penicillin, 100 g/ml of streptomycin
(Invitrogen), 2 mM glutamine (Merck), 44 mM sodium bicar-
bonate (Invitrogen), and 1mM sodiumpyruvate (Invitrogen). In
addition, BWTG3 and HepG2 cells had 0.1 mM nonessential
amino acids (Invitrogen) added to their medium. GT1-7 neu-
ronal cells (a kind gift from P. Mellon, University of California,
La Jolla, CA) were maintained in DMEM with 25 mM HEPES,
4500 mg/liter of glucose and pyroxidine, supplemented with
10% fetal bovine serum. AtT-20 (ATCC) pituitary tumor cells
in suspension were cultured in Kaighn’s modification of Ham’s
F-12K medium (Invitrogen), supplemented with 15% horse
serum and 2.5% fetal bovine serum.
Competitive Whole Cell Binding Assays—Assays were per-
formed essentially as described in Ref. 32 with the following
modifications. Forty-eight h after plating BWTG3 cells (2 105
cells/well in 24-well tissue culture plates) were washed three
times with pre-warmed phosphate-buffered saline (PBS) and
then incubated inmedium (minus FCSor penicillin-streptomy-
cin) with 20 nM [3H]Dex (specific activity of 89 Ci/mmol; AEC-
Amersham Biosciences) and varying concentrations of unla-
beled test compounds for 1 h at 37 °C. Cells were then placed on
ice and after 1 h washed three times, for 15 min each, with
ice-cold PBS containing 0.2% (w/v) bovine serum albumin
(BSA). Cells were lysed with 100 l of lysis buffer (PE Biosys-
tems) and binding was determined by scintillation counting.
Total binding was normalized to protein concentration (Brad-
ford assay) and expressed as percentage binding (top plateau for
Dex binding designated as 100% binding and bottom plateau as
0% binding).
Kinetic Whole Cell Binding Assays—Binding assays were
done in the presence of 1 nM [3H]Dex in the absence or pres-
ence of CpdA. For association binding experiments, binding
was measured for different times (0–240 min) after addition of
radioligand in the absence (total binding) or presence of 10 M
unlabeled Dex (nonspecific binding). The binding experiment
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then proceeded as described for competitive binding. Specific
binding (total binding nonspecific binding) was plotted. For
dissociation binding experiments, the cells were first incubated
in the presence of 1 nM [3H]Dexwith or without CpdA for 2 h at
37 °C after which the medium was replaced with fresh medium
without radioligand andCpdA. Binding at different time points
(0–240 min) proceeded as described for competitive binding
and plotted.
Reversibility of Whole Cell Binding Assay—The assay was
done by preincubating cells with 10MCpdA or 10MDex for
1 h at 37 °C. Cells were then washed three times with pre-
warmed PBS containing 0.2% (w/v) BSA and incubated for 1 h
at 37 °C with 1 nM [3H]Dex in the presence or absence of 10M
unlabeled Dex. The binding experiment then proceeded as
described for competitive binding. Specific binding (total bind-
ing nonspecific binding) was plotted.
Whole Cell Binding Assays to Determine Steroid Receptor
Content of BWTG3 Cells—This binding assay was done using
20 nM [3H]Dex (specific activity of 85 Ci/mmol; AEC-Amer-
sham Biosciences) for GR, 20 nM [3H]E2 (specific activity of
84 Ci/mmol; AEC-Amersham Biosciences) for ER, 20 nM
[3H]R5020 (specific activity of 84.6 Ci/mmol; AEC-Amer-
sham Biosciences) for PR, 20 nM [3H]mibolerone (specific
activity of 76.8 Ci/mmol; AEC-Amersham Biosciences) for
AR, and 9 nM [3H]aldosterone (specific activity of 87.9
Ci/mmol; AEC-Amersham Biosciences) for MR. Cognate
unlabeled ligands were added in 1000-fold excess. The bind-
ing experiment proceeded essentially as described for com-
petitive binding except that the incubation at 37 °C was done
for 4 h. Specific binding (total binding  nonspecific bind-
ing) was calculated in femtomole/mg of protein using a
counting efficiency of 40%.
Promoter Reporter Construct Studies—Cells (BWTG3,
HepG2, COS-1, GT1-7, and AtT-20 cells) were plated in rele-
vant complete medium at the densities indicated in the figure
legends. Cells were transfected 24 h later with constructs (as
indicated in figure legends) in medium without FCS or, for
GT1-7 and AtT-20 cells, medium with 10% dextran-coated
charcoal-stripped fetal bovine serum (Highveld Biologicals,
South Africa) using FuGENETM 6 transfection reagent (Roche
Applied Science) or for GT1-7 cells, with the Lipofectamine
method (Invitrogen), as described by the manufacturer. Cells
plated into 10-cm tissue culture dishes were replated 24 h after
transfection at the densities indicated in the figure legends. Test
compounds were added to cells 24 or 4 h (GT1-7 cells) after
transfection or replating and incubated for 24 or 20 h (GT1-7
cells). Induction in BWTG3, HepG2, and COS-1 cells occurred
inmediumwithout FCS and antibiotics except for assays inves-
tigating ER activity, where phenol red-free medium was used,
whereas induction in GT1-7 and AtT-20 cells occurred in
medium with 10% dextran-coated charcoal-stripped fetal
bovine serum. After induction cells were lysed with 100 l of
lysis buffer (PE Biosystems), and frozen at 20 °C. Luciferase
activitywas determined using the luciferase assay kit (Promega)
and -galactosidase activity was measured using the Galacto-
star assay kit (PE Biosystems) according to the manufacturer’s
instructions. Light emission was measured in a luminoskan
plate reader (Labsystems). Luciferase relative light units were
normalized with -galactosidase values to correct for transfec-
tion efficiency. For replated cells, protein concentration was
measured using the Bradford method and luciferase relative
light units normalized with protein concentrations to correct
for plating efficiency.
RNA Isolation—Twenty-four h after plating BWTG3 or
HepG2 cells (3 105 cells/plate in 10-cm tissue culture dishes)
mediumwas changed toOpti-MEM (Invitrogen) and cells were
incubated for a further 24 h. Cells were then treated with test
compounds for 72 (HepG2 cells) or 24 h (BWTG3 cells), and
total RNA was extracted according to the TRIzol method, as
described by the manufacturer (Sigma). After extraction, the
final RNA pellet was dissolved in 50 l of formazol (Molecular
ResearchCenter, Inc.) forNorthern blotting, or 50ml of diethyl
pyrocarbonate water for reverse transcription-PCR, and kept at
70 °C until used.
Northern Blotting—Northern blotting was essentially pre-
formed as previously described (33). Briefly, 20g of total RNA
was loaded and run on a 1% formaldehyde-agarose gel and
transferred to a nylon membrane (Hybond-N, Amersham
Biosciences). RNA was fixed on the membrane using a UV
cross-linker for 12 s. The membrane was prehybridized in a
hybridization oven at 50 °C for 1 h with pre-warmed “Dig easy
Hyb” solution (Roche Applied Science). Plasmids carrying
human CBG cDNA (cDNA kindly provided by G. L. Ham-
mond) were amplified in a DH5 competent Escherichia coli
strain and digested with EcoRI to obtain the CBG cDNA insert
of 1.2 kb. Hybridization was performed overnight at 50 °C with
[32P]CBG cDNA probes labeled with [-32P]deoxycytidine
triphosphate using the random priming technique (Amersham
Biosciences megaprime labeling kit). Membranes were washed
twice for 5 min in 2 SSC, 0.1% SDS at room temperature,
followed by two washes for 15 min in 0.1 SSC, 0.1% SDS at
50 °C.Membraneswere exposed between 24 and 48 h at70 °C
followed by densitometric scanning of the autoradiograms
using the UN-SCAN-IT program. Membranes were stripped
using a hot 0.5% SDS solution and reprobed with [32P]-actin
cDNA, provided by I. Parker, UCT, South Africa. Autoradiog-
raphy was for less than 24 h, followed by densitometric scan-
ning and normalizing the CBG values with the corresponding
-actin values.
Reverse Transcription-PCR—Total RNA (5 g) was reverse
transcribedwith oligo(dT)15 primers (Promega) using the avian
myeloblastosis virus reverse transcriptase enzyme (Promega)
and followed by a PCR on the obtained cDNA with Taq DNA
polymerase (Promega) and primers, specific for mouse glycer-
aldehyde-3-phosphate dehydrogenase, rCbg, and rTat (primer
sequences available on request).
Tyrosine Aminotransferase Assay—Twenty-four h after plat-
ing BWTG3 cells (2.5  105 cells/well/6-well tissue culture
plate) mediumwas changed tomediumwith stripped FCS for a
further 24 h. Cells were then treated with test compounds for
4 h after which cells were washed twice with PBS and lysed with
250 l of lysis buffer (10 mM Tris-HCl, pH 7.5, 0.25 M sucrose,
0.1 mM phenylmethylsulfonyl fluoride, and 10 g/ml of aproti-
nin) and frozen at 20 °C. On thawing, lysates were briefly
sonicated and centrifuged (10,000 g for 10 min at 4 °C). TAT
activity was determined according to the method of Diamond-
stone (34). TAT activity was expressed as absorbance at 330
nm/min and graphed as percentage of control.
Immunofluorescence Analysis—COS-1 cells were plated into
10-cm tissue culture dishes and transiently transfected 24 h
later with constructs as indicated in the figure legends using
FuGENE 6. Cells were replated 24 h later onto coverslips in
6-well plates in medium and at the densities indicated in the
figure legends. BWTG3 cells were grownon coverslips in 6-well
plates in complete medium at densities indicated in the figure
legends. Twenty-four h later cells were serum-starved for 24 h
inmedium as indicated in the figure legends. Cells were treated
with test compounds as indicated in the legends. After induc-
tion, cells were placed on ice, rinsed with 1ml of methanol, and
incubated at20 °C for 15 min with another 1 ml of methanol.
Cells were then washed three times with ice-cold PBS plus 0.2%
BSA and transferred to new 6-well plates containing 2 ml of
blocking buffer (PBS with 3% (v/v) newborn calf serum and 1%
(v/v) BSA). Cells were incubated for 1 h at room temperature
and then washed twice with ice-cold PBS plus 0.2% BSA. To
visualize GR, cells were incubated with the primary rabbit
anti-GR antibody, P-20 (Santa Cruz biotechnology) diluted
1:100 in blocking buffer for BWTG3 cells, orH-300 (SantaCruz
biotechnology) diluted 1:1000 in blocking buffer for COS-1
cells. To visualize c-myc-tagged GR cells were incubated
with a mouse anti-c-myc antibody, 9E10 (Sigma), diluted
1:500. Cells were then washed three times with ice-cold PBS
plus 0.2% BSA and incubated for 1 h at room temperature
with secondary antibody, Alexa Fluor 488-tagged or 594-
tagged anti-rabbit antibody (Molecular Probes) as indicated
in the figure legends, diluted 1:500 in blocking buffer. Nuclei
were visualized using either propidium iodide staining
including RNase (30 min at 37 °C), Hoechst 33258 stain
(Sigma, according to the manufacturer’s instructions), or
4,6-diamidino-2-phenylindole staining for 5 min at room
temperature as indicated in the figure legends. Cells were
then washed three times with ice-cold PBS, mounted on
glass slides, and analyzed using the microscopes indicated in
the figure legends. Cells were assessed for intracellular local-
ization of protein signal in a double-blind fashion with
45–50 cells counted in each sample. Cells were either allo-
cated to one of three groups, predominantly nuclear, pre-
dominately cytoplasmic, or evenly distributed between the
cytoplasm and nucleus or allocated as nuclear or not.
Co-immunoprecipitation—COS-1 cells (2  106 cells per
plate in 10-cm tissue culture dishes) were transiently trans-
fected 24 h after plating with 38.6 ng of hGR (19.3 ng of pEF-
FlaghGR and 19.3 ng of pEGFP-C2-GR) and 11.5g of pGL2-
basic using the DEAE-dextran method. Cells were re-plated
24 h later into 6-well plates (6 105 cells/well) in mediumwith
stripped FCS and after 24 h treated with ethanol, Dex (1M), or
CpdA (10 M) for 1 h. After induction cells were washed twice
with PBS before extraction on ice in Buffer A (10mMHepes, pH
7.5 (Invitrogen), 1.5 mMMgCl2, 10 mMKCl, 0.1% Nonidet P-40
(Roche Applied Science), and Complete Mini protease inhibi-
tor mixture (Roche Applied Science)). After two cycles of
freeze-thaw cells were collected, centrifuged at 14,000  g for
15 min, and the supernatant collected. Protein concentrations
were determined using the Bradford method and 20 g of pro-
tein/sample set aside forWestern blots (input). Lysates (200g
of protein/sample) were precipitated with 30 l of EZview Red
ANTI-FLAG M2 Affinity Gel beads (Sigma), pre-washed 4
times with Buffer A in the presence of 0.5% BSA, in a total
volume of 250l for 16 h at 4 °C. Beads were washed four times
with 200 l of Buffer A supplemented with 0.5% Triton X-100
(BDH) and 150 mM NaCl. 20 l of Laemmli buffer (62.5 mM
Tris-HCl, pH 6.8, 10% (v/v) glycerol, 1.25% (m/v) SDS,
0.00125% (m/v) bromphenol blue, and 2.5% -mercaptoetha-
nol) was then added to beads, which were boiled for 7.5 min at
95 °C. For Western blotting immune precipitates (20 l) were
separated on a 10% SDS-PAGE gel, together with the inputs of
total cell lysate (20 g). Following electrophoresis, proteins
were electroblotted and transferred toHybond-ECL nitrocellu-
lose membrane (Amersham Biosciences), which were probed
forGR (H-300 antibody fromSantaCruz Biotechnology diluted
1:3000) and visualized using ECL peroxidase-labeled anti-rab-
bit antibody (AEC-Amersham Biosciences) and ECL Western
FIGURE 1. Transrepression of promoter reporter constructs of three genes involved in the in vivo response to CpdA administration in rats. A, rat CBG.
BWTG3 cells (5104 cells/well in 24-well tissue cultureplates)were transiently transfectedwith 360ngof ratCbgpromoter reporter construct (ratCBG295Luc),
200 ng of pGL2-basic, and 40 ng of -galactosidase reporter plasmid (pPGKGeopbA). B, rat Pomc. AtT-20 cells (2.5 105 cells/well in 24-well tissue culture
plates) were transiently transfectedwith 240 ng of rat POMC promoter reporter construct (JA300), 60 ng of rat GR expression vector (pSVGR1), and 60 ng of rat
expressionvector forNur77 (CMX-Nur77).C,mouseGnrh.GT1-7 cells (1.25105 cells/well in 24-well tissue cultureplates)were transiently transfectedwith600
ng of mouse GnRH promoter reporter construct (3446mGnRHluc). Twenty-four (A and B) or 4 (C) h after transfection test compounds were added at a
concentration of 1 M. Control wells received an equal amount of ethanol. Cells were treated for 24 (A and B) or 20 (C) h, respectively. Luciferase values were
normalized for-galactosidase (A) or protein (B andC) values andplotted as a percentageof the average control S.E. (error bars). Statistical analysiswas done
to compare values in the presence of test compounds relative to the corresponding control using one-way analysis of variance followedbyDunnett’smultiple
comparisons post test (*, p 0.05; **, p 0.01).
blotting detection reagents (GE Healthcare) on Hyperfilm
(Amersham Biosciences).
Fluorescence Resonance Energy Transfer—COS-1 cells (2 
106 cells/plate in 10-cm tissue culture dishes) were transiently
transfected with 5.8 g of pECFP-hGR and 5.8 g of pEYFP-
hGR for the FRET experiment and 5.8g of pECFP-hGR, or
5.8 g of pEYFP-hGR, plus 5.8 g of pGL2-basic for controls
using the DEAE-dextran method.
Twenty-four h later cells were
replated (2  106 cells/well) into
8-well Lab-Tek chambered cover-
glass plates (Nunc) in medium with
stripped FCS. Twenty-four h after
replating cells were analyzed in the
temperature-controlled chamber
(37 °C) of an Olympus Cells system
attached to an IX 81 inverted fluo-
rescence microscope (Olympus
Corp.) equipped with an F-view-II-
cooled CCD camera (Soft Imaging
Systems). The light source was a
150-watt xenon lamp, part of the
MT20 excitation source. Cells were
observed with a 60 objective lens
and theCell imaging software used
for image acquisition and analysis.
The YFP filter set excites at S500/
20x (Chroma) and emission is
detected at S535/30m, whereas the
CFP filter set excites at S430/25x
and emission is detected at S470/
30m. Cells that express similar
CFP-GR and YFP-GR levels were
selected and treatedwith solvent, 10
M CpdA or 10 M Dex in DMEM
containing no supplements. CFP,
YFP, and FRET images were taken
every minute over a 30-min period.
FRET fluorescence was detected
using a filter set with S430/25x exci-
tation and S535/30m emission. An
exposure time of 1500 ms at 100%
light intensity was used. The signals
measured in the FRET channel were
corrected for cross-talk from the
cyan and yellow channels using the
following equation: nFRET FRET
signal  (a  YFP signal)  (b 
CFP signal). n is normalized FRET
and a and b were determined by
measuring the crossover into the
FRET channel of the YFP and CFP
signals, respectively, in cells ex-
pressing each fusion protein on its
own (35). In our system, 59% of
the CFP signal and 2.6% of the YFP
signal were detected in the FRET
channel. Background subtraction
was carried out using an area where no cells were present.
RESULTS
CpdA Causes Transrepression of Promoter Reporter Con-
structs of Three Genes Involved in the in Vivo Response to CpdA
Administration in Rats—CpdA administration was previously
shown to significantly repress CBG, ACTH, and LH levels in
FIGURE2.Transrepressionof the ratCbgproximalpromoter reporter construct andendogenousgene in
liver cell lines. A, dose-response curves of transrepression of the rat CBG295Luc promoter reporter construct
by CpdA andDex in the presence of endogenous GR. The rat CBG295Luc promoter reporter construct (360 ng)
plus 200 ng of pGL2-basic and 40 ng of pPGKGeopbAwere transiently transfected into BWTG3 cells (5 104
cells/well in 24-well tissue culture plates). Twenty-four h after transfection cells were treated with increasing
concentrations of test compounds, as indicated, and lysed after 24 h. Control wells received an equal amount
of ethanol. Luciferase values were normalized for -galactosidase and plotted as a percentage of the average
control S.E. (error bars). Log EC50 and percentage repression values were determined by fitting a sigmoidal
dose-response curvewith the variable slope.B, transrepressionof humanCBGmRNA.HepG2cellswere treated
with Dex (1 M) or CpdA (10 M) for 72 h. Control wells received an equal amount of ethanol. Total RNA was
analyzed with Northern blot analysis, using hCBG cDNA, stripped, and reprobed with -actin to control for
loading. CBG results are presented as normalized relative to -actin and as % of average control S.E. (error
bars). Statistical analysis was done to compare values in the presence of test compounds relative to the corre-
sponding control using one-way analysis of variance followed by Dunnett’s multiple comparisons post test (*,
p0.05; ***,p0.001).C, transrepressionof the rat CBG295Lucpromoter reporter construct byCpdAandDex
in the absence or presence of co-transfected rGR and RU486. BWTG3 cells (5 104 cells/well in 24-well tissue
culture plates) were transiently transfected with rat CBG295Luc (360 ng), 200 ng of rGR (pSVGR1) or pGL2-
basic as indicated, and 40 ng of pPGKGeopbA. Twenty-four h after transfection, test compoundswere added
(CpdA at 10 M; Dex at 1 M; RU486 at 20 M) and cells were lysed after 24 h. Control wells received an equal
amount of ethanol. Luciferase values were normalized for -galactosidase and plotted as a percentage of the
average control  S.E. (error bars). Statistical analysis was done to (i) compare values in the presence of test
compounds relative to the corresponding control using one-way analysis of variance followed by Dunnett’s
multiple comparison’s post test (*, p  0.05; **, p  0.01), and to (ii) compare values without GR (rGR) to
values with co-transfected GR (rGR) and RU486 (RU486) for each compound tested using one-way anal-
ysis of variance followed by Dunnett’s multiple comparisons post test (a, p 0.05; b, p 0.01; c, p 0.001).
Wistar rats, while concomitantly
increasing free corticosterone levels
(5). Whereas this repression by
CpdA might be attributed to the
increase in biologically active corti-
costerone, the possibility of direct
action of CpdA via the GR was not
precluded. To test this assumption,
we investigated the direct transcrip-
tional effect of CpdA in cell lines on
the promoter reporter constructs of
Cbg, Pomc, andGnrh. The latter two
promoters were chosen as the Pomc
gene encodes the precursor to
ACTH (36), whereas GnRH levels
reflect circulating LH levels (37). It
is clear (Fig. 1) that CpdA, like Dex,
significantly (p 0.05) represses all
three promoter reporter constructs.
CpdATransrepresses RatCBGvia
a GR-dependent Mechanism in
Hepatic Cell Lines but Does Not
Transactivate GRE-containing Pro-
moters or Genes—Having shown
that CpdA transrepresses, we chose
to focus on the CBG promoter, as
little work has been done on GC
responsiveness of this promoter in
contrast to the POMC and GnRH
promoters. Dose-response curves of
rat CBG promoter reporter transre-
pression in BWTG3 cells (Fig. 2A)
revealed no significant (p 	 0.05)
difference between the potency (log
EC50) of Dex (8.43) and CpdA
(8.93). However, analysis of the
efficacy (maximal repression) indi-
cates that Dex represses 34.5 
2.7%, which is significantly (p 
0.05) more than CpdA (24.7 
3.8%). Both CpdA and Dex also sig-
nificantly repressCBGmRNA levels
in HepG2 (Fig. 2B) and BWTG3
cells (supplemental Fig. S1), which
establishes that transcriptional reg-
ulation of the Cbg promoter corre-
lates with regulation at the mRNA
level.
To test whether transrepression
potential is dependent on the GR,
BWTG3 cells were co-transfected
with the rat GR expression vector
(rGR) in the presence of the rat
CBG295Luc reporter construct
(Fig. 2C, closed bars). Co-transfec-
tion with rGR in BWTG3 cells sig-
nificantly increased the transrepres-
sion response of Dex (p 0.01) and
CpdA (p  0.05). To strengthen the case that the observed
repression of the rat CBG295Luc promoter reporter construct
by CpdA was mediated by the GR, the effect of the glucocorti-
coid antagonist, RU486, on transrepression in BWTG3 cells
was also investigated (Fig. 2C, hatched bars). RU486 relieved
the transrepression observed in the presence of both CpdA and
Dex suggesting that repression of the rat CBG295Luc promoter
reporter construct by Dex, as well as CpdA, is mediated by
the GR.
Having shown that CpdA can result in transrepression of
GC-responsive genes, such as Cbg, we were interested in
whether it could also result in transactivation of GC-respon-
sive genes and thus evaluated the ability of CpdA to transac-
tivate two GRE-containing promoters. BWTG3 cells were
transiently transfected with a (GRE)2tkLuc (Fig. 3A) or a
(GRE)250hIL6PLuc promoter reporter construct (supple-
mental Fig. S2A). The result with both constructs shows that
in the presence of endogenous GR (Figs. 3A and supplemen-
tal S2A, open bars), Dex significantly (p  0.01) transacti-
vates the GRE-dependent promoter constructs while
co-transfection of rat GR (Figs. 3A and supplemental S2A,
closed bars) almost doubled the transactivation response of
Dex. However, even at 10 times the concentration of Dex,
CpdA did not result in transactivation, even when GR was
co-transfected. The glucocorticoid antagonist, RU486, abol-
ishes Dex (Figs. 3B and supplemental S2B, hatched bars)
transactivation but CpdA does not. Dex, but not CpdA, up-
regulates TAT mRNA (Fig. 3C) and protein activity levels
(Fig. 3D) in BWTG3 cells, which confirms the inability of
CpdA to transactivate an endogenous gene containing a GRE
motif.
CpdA Binds Reversibly to the Mouse GR, Influences Associa-
tion of [3H]Dex but Has No Effect on Dissociation, and Causes
Nuclear Translocation of GR—Binding of CpdA to mGR was
investigated, using whole cell competitive binding, in BWTG3
cells that express endogenous GR (Fig. 4A). CpdA binds GR
with a significantly (p 0.05) lower affinity (Kd 81.8 nM) than
Dex (Kd  1.29 nM). In addition, CpdA displayed an atypical
binding curve in displacing only 47% of the [3H]Dex. CpdA can
cyclize to an aziridine with alkylating potential (2) and thus to
eliminate the possibility that CpdA is covalently modifying the
GR and thus changing its affinity for Dex, BWTG3 cells were
preincubated with CpdA or Dex, thoroughly washed, and then
tested for binding of [3H]Dex (supplemental Fig. S3). Kinetic
GR binding studies (Fig. 4B) show that CpdA slows the associ-
ation of Dex resulting in a significant (p 0.01) increase in the
half-life (t1⁄2) of association (from 9.01 min in the absence of
CpdA to 17.45 min in the presence of 10 M CpdA), but that it
does not significantly (p 	 0.05) affect the dissociation of Dex
from GR.
Kinetic studies of the nuclear translocation of GR in COS-1
cells transiently transfected with rat GR (Fig. 4C) show that the
nuclear import rate (t1⁄2) induced by CpdA is not significantly
(p 	 0.05) slower than that induced by Dex. However, the
nuclear localization plateaus at a significantly (p 0.01) lower
level than seen with Dex (68.6 3.4% nuclear for CpdA versus
95.8  2.6% nuclear for Dex). These results are comparable
with those found in BWTG3 cells where CpdA (1M), like Dex
(1M), induces nuclear translocation of endogenous GR, albeit
to a slightly lesser degree (72% nuclear) than Dex (100%
nuclear) at 30 min (supplemental Fig. S4).
CpdA, Unlike Dex, Does Not Induce Dimerization of the GR—
It has been postulated that the dissociated GC behavior could
result from differential interaction of the liganded GR with co-
activators and co-repressors (38) or from loss of GR dimeriza-
tion (16, 39). We investigated the latter mechanism using a
co-immunoprecipitation assay of transiently transfected
FLAG- and GFP-tagged GR, immunoprecipitated with FLAG
antibody, which shows that CpdA, unlike Dex, does not result
in enrichment of GFP-tagged GR and thus GR dimerization
(Fig. 5A). In fact CpdA appears to decrease baseline GR dimer-
ization as confirmed with FRET (Fig. 5B), where addition of
CpdA results in a decrease in FRET indicating a decrease in GR
dimerization, whereas addition of Dex results in an increase in
FRET indicating an increase in GR dimerization. The inability
of CpdA to elicit GR dimerization is further confirmed with an
elegant approach first used by Savory et al. (40). Briefly, a
c-myc-tagged, nuclear localization signal 1 (NL1)-deficient
mutant GR (myGRNL1) is co-transfected with wtGR in COS-1
cells (Fig. 5C). Co-transfection of the wtGR, with an intact NL1,
enables the defective mutant GR (myGRNL1) to translocate to
the nucleus within the context of a wtGR:myGRNL1 dimer
FIGURE 3. Transactivation of a GRE-containing promoter reporter construct and endogenous gene in a liver cell line. A, transactivation of a GRE-
containing promoter by CpdA and Dex in BWTG3 cells, in the absence or presence of co-transfected rGR. BWTG3 cells (5 104 cells/well in 24-well tissue
culture plates) were transiently transfected with 360 ng of GRE-driven promoter reporter construct ((GRE)2tkLuc), 200 ng of rGR (pSVGR1) or pGL2-basic as
indicated, and 40 ng of pPGKGeopbA. Twenty-four h after transfection, test compounds were added (CpdA at 10M; Dex at 1M) and cells were lysed after
24 h. Control wells received an equal amount of ethanol. Luciferase values were normalized for -galactosidase and values plotted as a percentage of the
average control S.E. (error bars). Statistical analysis was done to (i) compare values in the presence of test compounds relative to the corresponding control
using one-way analysis of variance followed by Dunnett’s multiple comparison’s post test (*, p  0.05; **, p  0.01) and to (ii) compare values without GR
(rGR) to values with co-transfected GR (rGR) for each compound tested using a two-tailed unpaired t test (a, p 0.05; b, p 0.01). B, transactivation of
GRE-containing promoter by CpdA and Dex in BWTG3 cells, in the absence or presence of RU486. The (GRE)2tkLuc promoter reporter construct (360 ng) was
transiently transfected intoBWTG3cells (5104 cells/well in 24-well tissue cultureplates), togetherwith 200ngof rGR (pSVGR1) and40ngofpPGKGeopbA.
Cells were treated with 10 M test compounds as indicated. Control wells received an equal amount of ethanol. Luciferase values were normalized for
-galactosidase andplotted as a percentageof the average S.E. transactivationbyDex alone. Statistical analysiswas done to compare values in thepresence
of test compounds relative to the corresponding controls usingone-wayanalysis of variance followedbyDunnett’smultiple comparison’s post test (*,p0.05;
**, p 0.01; ***, p 0.001). C, transactivation of TATmRNA. BWTG3 cells were treatedwithDex (1M) or CpdA (10M) for 72 h. Control wells received an equal
amount of ethanol. Total RNA was reverse transcribed and the cDNA obtained subjected to PCR analysis with primers to detect mTAT and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (housekeeping gene used as an internal control) in separate reactions. PCR products were separated on agarose gel and
visualizedunderUV light after EtBr staining. The figure is representative of three independent experiments.D, transactivationof TAT activity. BWTG3 cellswere
treatedwith Dex (1M) or CpdA (10M) for 4 h. Control wells received an equal amount of ethanol. Cell lysatewas prepared and assayed for TAT activity S.E.
(error bars). Statistical analysis was done to compare values in the presence of test compounds relative to control using one-way analysis of variance followed
by Dunnett’s multiple comparisons post test (*, p 0.05).
where the wtGR NL1 suffices for translocation of the dimer.
Transfection of the wtGR alone was visualized by anti-GR anti-
body and confirms that Dex andCpdA can cause nuclear trans-
location of the wtGR (Fig. 5C, I, closed bars). Transfection with
the nuclear translocationmutant, myGRNL1, alone (Fig. 5C, II)
was visualized using an anti-myc antibody and shows that nei-
ther Dex nor CpdA can cause substantial nuclear translocation
of this mutant GR and thus the GR remainsmainly cytoplasmic
(Fig. 5C, II, open bars). However, if the wtGR is cotransfected
with the nuclear translocation mutant GR (Fig. 5C, III) and just
the mutant receptor is visualized with an anti-myc antibody,
nuclear translocation (Fig. 5C, III, closed bars) of themutantGR
is only observed with Dex (89% nuclear at 10 M), but not with
CpdA (5% nuclear at 10 M).
Implications of Loss of GR Dimerization Induced by CpdA—
To test the implications of the loss ofGRdimerization observed
with CpdA we investigated the behavior of Dex and CpdA via
both wild type GR (wtGR) and a GR dimerization mutant
(GRdim) (16). Nuclear import (Fig. 6A) shows that, although
there is no significant (p 	 0.05) difference in nuclear import
rate (t1⁄2), the maximal import is significantly (p 0.01) higher
for Dex via wtGR (93.28  1.40%) than for Dex via GRdim
(75.76  3.18%), which is not significantly different from that
attained with CpdA via wtGR (65.83  1.19%) or CpdA via
GRdim (64.60  3.91%). Nuclear export (Fig. 6B) in contrast
does show a significant (p 0.05) difference in nuclear export
rate (t1⁄2) between Dex via wtGR (18.74  1.56 h) and Dex via
GRdim (12.15  0.32 h), CpdA via wtGR (12.56  0.62 h), and
CpdA via GRdim (7.89  0.95 h). Transactivation of a GRE-
containing promoter construct (Fig. 6C) indicates that Dex,
unlike CpdA, significantly (p  0.001) transactivates through
wtGR, but not viaGRdim. This is in contrast to the ability ofDex,
like CpdA, to repress the Cbg (Fig. 6D) and Il-6 (Fig. 6E) pro-
moters via both wtGR and GRdim.
Steroid Receptor Specificity of CpdA—Having established
that CpdA repression of Cbg is via the GR (Fig. 2), we set out
to test the steroid receptor specificity of CpdA in COS-1
cells transiently transfected with GR,MR, PR, AR, or ER (Fig.
7). To test for transactivation via GR, MR, PR, and AR a
GRE-containing promoter reporter was co-transfected as
these receptors share a consensus response element (41, 42),
whereas for transactivation via ER an ERE-containing pro-
moter reporter was co-transfected. An NFB-binding site-
containing promoter reporter was cotransfected to test for
transrepression. The agonists used were Dex for GR, aldos-
terone for MR, R5020 for PR, DHT for AR, and E2 for ER,
whereas the antagonists used were RU486 for GR, spirono-
lactone for MR, RU486 for PR, hydroxyflutamide for AR, and
ICI 182,780 for ER. Both agonist and antagonist modes were
tested and the results show that under these conditions
CpdA acts as an AR antagonist in transactivation and as a
GR, MR, PR, and ER agonist in transrepression.
The promiscuous steroid receptor specificity of CpdA in
transrepression via the NFB-binding site, using COS-1 cells
and PMA as a stimulus, was of concern, especially as previous
data had shown transrepression of a NF-B-driven promoter
construct only via GR when using tumor necrosis factor as a
proinflammatory stimulus in HEK293T cells (6). Therefore,
further investigation focused on transrepression in the context
of theCbg proximal promoter and at theCBGprotein level. The
Cbgpromoter is only significantly (p 0.001) transrepressed by
CpdA and the cognate agonist via the GR and not via the other
steroid receptors (Fig. 8A). As steroid receptor levels were quite
low in this experiment we investigated transactivation of a
GRE- or ERE-containing promoter reporter at the same levels
FIGURE 4. Binding of CpdA to rodent GR and translocation to nucleus.
A, competitivewholecellbinding inBWTG3cellsof20nM[3H]Dex inthepresence
of increasing concentrations of unlabeled Dex or CpdA. The results shown are
from two independent experiments performed inquadruplicate. Points indicate
averageS.E. Curve fittingwasperformedusingnon-linear regressionandone-
site competition to obtain log EC50 and maximal displacement. Ki values were
obtained using the method of Cheng and Prusoff (68). B, kinetics of binding in
BWTG3cellsof 1nM [3H]Dex in theabsence (0MCpdA)andpresenceofCpdA (1
and 10 M). The results shown are from three independent experiments per-
formed in triplicate S.E. (error bars). To obtain t1⁄2 curve fitting was performed
using non-linear regression and one phase exponential association and one
phase exponential decay, respectively. C, nuclear translocation of transiently
transfected rGR in COS-1 cells. pTC2-wtGRrat (11.6 g) was transiently trans-
fected into COS-1 cells (2  106 cells/plate in 10-cm tissue culture dishes) and
replated24h later (3105 cells/well in a6-well plate) intoDMEMsupplemented
with 10%strippedFCS for 24hbeforebeing treatedwithDex (1M) or CpdA (10
M) for 0, 2, 4, 6, 10, 15, 20, 40, or 60 min. After fixation, cells were subjected to
immunostaining with rabbit anti-GR, followed by anti-rabbit Alexa 488 as a
secondary antibody. Hoechst 33258 stain was used to visualize nuclei. Cells
were analyzed using an IX 81 Olympus microscope. The percentage of cells
showing nuclear localization of GR was quantified for three independent
experiments S.E. (error bars). One-phase exponential association curve fit-
ting was conducted to determine t1⁄2 and maximal localization.
FIGURE5.Dex,butnotCpdA, results in ligand-induceddimerizationof theGR inCOS-1cells.A, co-immunoprecipitationofdifferentially taggedGR.COS-1
cells were transiently transfected with FLAG-tagged GR (pEFFlaghGR, mass 96 kDa), GFP-tagged GR (pEGFP-C2-GR, mass 128.5 kDa), and pGL2-basic and
treatedwith ethanol (control), 106 MDexor 105 MCpdA for 1h. Cellular extractswere immunoprecipitatedwith anti-FLAGbeads.Westernblotswereprobed
with anti-GR antibody. The figure is representative of three independent experiments. B, FRET analysis of GR dimerization. COS-1 cells were transiently
transfectedwithCFP-taggedGR (pECFP-hGR) andYFP-taggedGR (pEYFP-hGR) and treatedwith ethanol (control), 105 MDexor CpdA for 30minwhile FRET
intensity was monitored on the Olympus IX 81motorized invertedmicroscope at 37 °C. Corrected FRET is plotted against time. The figure is representative of
three independent experiments.C,Dex, but not CpdA, induces nuclear localization of theGRmutantwhen co-transfectedwithwtGR inCOS-1 cells. COS-1 cells
(3 106 per plate in 10-cm tissue culture dishes) were transfected (I) with 12g ofWT rat GR (pSVGR1) alone (wtGR), (II) with 12g of c-myc-tagged nuclear
translocationmutant GR alone (myGRNL1), or (III) with 12gDNA in an 8:1 ratio ofwtGR:myGRNL1(wtGR:myGRNL1) and replated 24 h later (5 10
5 cells/well
in a 6-well plate) into Opti-MEM for 24 h before induction with Dex (1 or 10 M) or CpdA (1 or 10 M) for 60 min. Control wells received an equal amount of
ethanol. Localization of constructs was visualized as follows: (I) wtGR alone by indirect immunofluorescence using a rabbit anti-GR antibody followed by an
Alexa Fluor 594-tagged anti-rabbit antibody (anti-GR; red); (II and III) myGRNL1 alone or wtGR:myGRNL1 by indirect immunofluorescence using a mouse
anti-c-myc antibody followedby anAlexa Fluor 488-tagged anti-mouse antibody (anti-myc; green). Nucleiwere visualizedwith 4,6-diamidino-2-phenylindole
staining (blue). Cells were analyzed using a Zeiss confocal LSM410 microscope. The percentage of cells showing nuclear (closed bars), both (hatched bars), or
cytoplasmic (open bars) localization of GR was quantified for three independent experiments and is presented graphically S.E. (error bars). Representative
micrographs for control, Dex (10 M), and CpdA (10 M) are presented to the right of each graph.
of transfected steroid receptors and found that the receptors
were active at these concentrations (supplemental Fig. S5). In
addition, at the CBG protein level only Dex and CpdA, but not
the other steroid receptor ligands, show significant (p  0.01)
transrepression via endogenous steroid receptors in BWTG3
cells (Fig. 8B). Whole cell binding assays indicate that BWGT3
cells contain mainly GR, ER, and PR
and little AR and MR (Fig. 8B, table
inset). Thus taken in isolation these
results (Fig. 8B) only support the
findings that repression of Cbg by
CpdA in BWTG3 cells occurs
through GR. However, if the results
are considered together with that in
Fig. 8A it suggests increased steroid
receptor specificity of CpdA in the
context of the Cbg promoter and at
CBG protein levels. Interestingly,
the antagonism of the AR by CpdA
observed with a GRE-containing
promoter reporter (Fig. 7A) is con-
firmed at the protein activity level,
with CpdA, like hydroxyflutamide,
significantly (p  0.001) antagoniz-
ingDHT transactivation of the TAT
protein activity levels in BWTG3
cells transfected with AR (Fig. 8C).
DISCUSSION
Glucocorticoids remain the most
effective treatment for a variety of
inflammatory diseases but pro-
longed treatment, especially at high
doses, results in severe side effects
(39, 43). Selective GR agonists that
retain the beneficial anti-inflamma-
tory action of GCs but display fewer
side effects are actively sought. Spe-
cifically, it has been suggested that
compounds that dissociate between
transactivation involved in many of
the side effects of GCs, and trans-
repression, the major mechanism
whereby GCs mediate their anti-in-
flammatory action, may be useful
(12, 44, 45). Recently, several com-
pounds displaying such dissociation
both in vitro and in vivo have been
reported: AL-438 (38), ZK 209614
(46), and CpdA (6, 28).
CpdA was initially described
within the context of contraception
in rats (1), where in vivo studies in
rats showed decreases in CBG,
ACTH, and LH levels (5). Our
results suggest that repression of
these proteins is due to a direct tran-
scriptional effect of CpdA.
CBG is a central player in GC disposition and of interest in
inflammation as a negative acute-phase protein (47) and
modulator of the acute-phase response (48), (49). Our
results strongly support a mechanism whereby CpdA results
in GR-mediated repression of the Cbg gene, as additional
co-transfected GR increased transrepression, whereas addi-
FIGURE 6. Implications of loss of GR dimerization induced by CpdA. A, nuclear import of transiently trans-
fected mouse GR and mouse GRdim mutant in COS-1 cells. COS-1 cells (2  106 cells/plate in 10-cm tissue
culture dishes) were transiently transfected with 7.5 g of pcDNA3.1-GRWT or pcDNA3.1-GRdim and replated
24 h later (3 105 cells/well in a 6-well plate) in DMEM supplemented with 10% stripped FCS. After 24 h cells
were treated with Dex (1 M) or CpdA (10 M) for 0, 2, 4, 6, 10, 20, 30, 45, or 60 min. After fixation, cells were
subjected to immunostainingwith anti-GR, followedbyanti-rabbitAlexa488as a secondary antibody.Hoechst
33258 stainwas used to visualize nuclei. Cells were analyzed using an IX 81Olympusmicroscope. The percent-
age of cells showing nuclear localization of GRwas quantified for three independent experiments S.E. (error
bars). One-phase exponential association curve fitting was conducted to determine t1⁄2 and maximal localiza-
tion. B, nuclear export of transiently transfectedmouseGR andmouseGRdimmutant in COS-1 cells. COS-1 cells
(2 106 cells/plate in 10-cm tissue culture dishes) were transiently transfectedwith 7.5gof pcDNA3.1-GRWT
or pcDNA3.1-GRdim and replated 24 h later (3 105 cells/well in a 6-well plate) in DMEM supplemented with
10% stripped FCS for 24 h before being treated with Dex (1 M) or CpdA (10 M) for 45 min, washed, and
monitored over 0, 4, 8, 12, 20, 24, and 28 h. After fixation, cells were subjected to immunostaining with rabbit
anti-GR, followed by anti-rabbit Alexa 488 as a secondary antibody. Hoechst 33258 stain was used to visualize
nuclei. Cells were analyzed using an IX 81 Olympus microscope. The percentage of cells showing nuclear
localization of GRwas quantified for three independent experiments S.E. (error bars). One phase exponential
decay curve fitting was conducted to determine t1⁄2. C, transactivation of the transiently transfected GRE-
containing promoter reporter construct via mouse GR or mouse GRdim mutant. COS-1 cells (1 104 cells/well
in 96-well tissue culture plates) were transiently transfected with 100 ng of pTAT-GRE2-Elb-luc, 10 ng of
pcDNA3.1-GRWT or pcDNA3.1-GRdim as indicated, and 10 ng of pPGKGeopbA. Twenty-four h after transfec-
tion cells were induced with Dex (1 M) or CpdA (10 M) for 24 h. Control wells received an equal amount of
ethanol. Luciferase valueswere normalized for-galactosidase and values plotted as fold-induction relative to
average control S.E. (error bars). D, transrepression of the transiently transfected rat CBG295Luc promoter
reporter construct viamouseGRormouseGRdimmutant. COS-1 cells (2106 cells/plate in 10-cm tissue culture
dishes) were transiently transfected with 9g of CBG295Luc and 3 ng of pcDNA3.1-GRWT or pcDNA3.1-GRdim
as indicated. Twenty-four h after transfection cells were replated (5 104 cells/well in 24-well tissue culture
plates). Cells were induced for 24 hwith Dex (1M) or CpdA (10M) 24 h after replating. Control wells received
an equal amount of ethanol. Luciferase valueswere normalizedwith protein concentration and values plotted
as fold-induction relative to average control S.E. (error bars). E, transrepression of the transiently transfected
IL6-luc promoter reporter construct via mouse GR or mouse GRdim mutant. COS-1 cells (2 106 cells/plate in
10-cm tissue culture dishes) were transiently transfected with 9 g of p(IL6B)350hu.IL6Pluc and 0.9 g of
pcDNA3.1-GRWTor pcDNA3.1-GRdim as indicated. Twenty-four h after transfection cellswere replated (5 104
cells/well in 24-well tissue culture plates). Cells were induced for 24 hwith PMA (10 ng/ml) alone orwith Dex (1
M) or CpdA (10M) 24 h after replating. Control wells received an equal amount of ethanol. Luciferase values
were normalized with protein concentration and values plotted as percentage induction with PMA induction
alone as 100%  S.E. (error bars). Statistical analysis was done to compare values in the presence of test
compounds relative to the corresponding control (C andD) or PMA induction alone (E) using one-way analysis
of variance followed by Dunnett’s multiple comparisons post test (*, p 0.05; **, p 0.01; ***, p 0,001).
tion of the GR antagonist, RU486, abrogated CpdA-induced
transrepression.
CpdA, however, was unable to induce transactivation of
GRE-containing promoter-reporter constructs or to induce an
increase in TAT mRNA or activity. TAT, a liver enzyme,
involved in gluconeogenesis, is up-regulated by GCs (50) and is
involved in the metabolic side effects of GC therapy (39). Thus
CpdA does not act as either a GR agonist or antagonist in trans-
activation of GRE-containing promoter reporters or endoge-
nous genes despite acting as an agonist in repressing CBG. The
ability of CpdA to dissociate transrepression from transactiva-
tion shown previously in the context of inflammation (6, 28),
and prostate cancer (51) is thus confirmed and strengthened by
our biochemical results.
Our results also show that CpdA binds reversibly to the
endogenous GR in BWTG3 cells with an affinity that is about
63-fold less than that for Dex, which is in contrast to previous
results in L929sA cells (6) where CpdA was shown to have a
4-fold higher affinity for the GR than Dex. The results do, how-
ever, agree with those in DU145 cells (51) where CpdA was
shown to bind the GR to a lesser extent than Dex. In addition,
we also confirmed previous work showing that CpdA causes
nuclear translocation of the GR (6, 28, 51). Interestingly, how-
ever, we show that although the nuclear import rate is similar,
GR treated with CpdA does not result in full nuclear
localization.
It has been suggested that GR ligands that dissociate transre-
pression from transactivationmay be identified by selecting for
compounds that prevent dimerization of the GR, as transgenic
mice expressing a dimerization-deficientGR (GRdim/dim) retain
transrepression, but not transactivation, capacity (16). Our
results, in agreement with a previous study (28), indeed show
that CpdA prevents ligand-induced dimerization, whereas
FRET studies show that CpdA in fact decreases basal GR
dimerization.
Using a GRdimmutant (22) we show that the behavior of Dex
via this mutant is comparable with that of CpdA via the wtGR.
Dex-induced nuclear localization of the GRdim mutant is simi-
lar to that induced by CpdA via the wtGR in that full nuclear
localization is not attained in import studies, whereas in export
studies the export rate (t1⁄2) is similar for CpdA via thewtGR and
Dex via theGRdimmutant. In addition,we show thatDex via the
GRdim mutant, like CpdA via the wtGR, cannot transactivate a
GRE-containing promoter. Transactivation of GRE-containing
genes is generally mediated through direct binding of the GR to
DNA (9, 10) and is suggested to require GR dimerization (16,
52), which neither CpdA acting through wtGR nor Dex acting
via the GRdim mutant would elicit. Thus these results strongly
support the idea that the lack of CpdA-induced dimerization of
the GRmay contribute to its inability to transactivate. Transre-
pression by theGR, in contrast,may be via negativeGREs, or via
a tethering mechanism that does not require DNA binding by
theGR, but rather protein-protein interactionswith other tran-
scription factors (10, 53, 54). The firstmechanism is reported to
require dimerization of the GR, whereas the latter mechanism
may be mediated by monomeric GR (9, 55). We show that
CpdA acting via the wtGR, like Dex via the GRdim mutant, can
repress an Il-6 promoter construct. This construct contains
three NFB elements binding NFB proteins that have been
shown to interact with GR via a tethering mechanism (10, 14),
which does not require GR dimerization (16). In addition, we
show that the Cbg promoter is repressed as effectively by Dex
acting via the GRdim mutant as through the wtGR illustrating
that dimerization of the GR is not required for transrepression.
Although plasma levels of CBG are suppressed during pro-
longed administration of GCs, and physiological and physical
stressors (56) and GCs decrease rat Cbg hepatic transcription
(57), promoter studies that identify possible cis-acting
sequence elements involved in GC regulation are lacking, nor
have negative GREs been identified in the Cbg promoter (17).
Our results thus suggest that CpdA and Dex repression of Cbg
gene expression does not require GR dimerization and there-
fore probably proceeds via a tetheringmechanism.The fact that
the Pomc (58, 59) and Gnrh (18) promoters, which we show to
be repressed by CpdA, have also been reported to be repressed
by the GR via a tethering mechanism strengthens this
hypothesis.
Although our results suggest that CpdA acts via the GR in
transrepression of Cbg gene expression, investigation of CpdA
action via other receptors yielded some unexpected results
when promoters containing transcription binding sites, specif-
ically for GRE and NFB, were investigated in COS-1 cells.
CpdA acts as an AR antagonist in transactivation of a GRE-
binding site containing the promoter reporter in our cellmodel.
This agrees with previous work (51, 60), however, we did not
find the antagonism of transactivation via the GR shown by
Yemelyanov et al. (51) nor did we observe PR antagonism as
shown by Tanner et al. (60). Whether the discrepancies related
to GR and PR antagonism reflect differences in the ligand used
or depend on clonal variation in post-translational receptor
modifications and/or receptor protein stability of cell lines used
is not clear yet. Nevertheless, both our work and previous
results (51, 60), indicate that CpdA does not act as an agonist in
transactivation.
With respect to transrepression our results show that CpdA
is not only a GR agonist but may also act via MR, PR, and ER in
transrepressing a NFB-binding site containing promoter
reporter in COS-1 cells induced with PMA. This is in contrast
to previous work investigating transrepression, via the same
construct, but in HEK293T cells, with tumor necrosis factor
FIGURE7.Steroid receptor specificityofCpdA.A, transactivationof transiently transfectedGRE-containingpromoter reporter construct viaGR,MR, PR, orAR,
or ERE-containing promoter reporter construct via ER. COS-1 cells (1 105 cells/well in 24-well tissue culture plates) were transiently transfected with 300 ng
of pTAT-GRE2-Elb-luc, 30 ng of pPGKGeopbA, and 30 ng of pRS-hGR, pRS-hMR, pSG5hPRB, or pSVARo as indicated, or 1200 ng of pGL2–3x-ERE-TATA-luc, 30
ng of pPGKGeopbA, and 30 ng of pcDNA3-ER. Twenty-four h after transfection cells were induced for 24 hwith solvent (ethanol), agonist (106 M), or CpdA
(105 M) (agonist mode), or with agonist (106 M), agonist (106 M) plus antagonist (106 M), or agonist (106 M) plus CpdA (105 M) (antagonist mode).
Luciferase values were normalized with -galactosidase and values plotted as fold-induction S.E. (error bars) relative to average solvent. Statistical analysis
was done to compare values in the presence of test compounds relative to solvent (*, p 0.05; **, p 0.01; ***, p 0.00) for agonist mode or corresponding
agonist ($, p 0.05; $$, p 0.01; $$$, p 0.001) for antagonistmodeusing one-way analysis of variancewithDunnett’smultiple comparisons test as post test.
B, transrepression of transiently transfected IL-6 promoter reporter construct via GR, MR, PR, AR, or ER. COS-1 cells (2 106 cells/plate in 10-cm tissue culture
dishes)were transiently transfectedwith 9gof p(IL6B)350hu.IL6Pluc and 0.9gof pRS-hGR, pRS-hMR, pSG5hPRB, pSVARo, or pcDNA3-ER as indicated.
Twenty-four h after transfection cells were replated (5 104 cells/well in 24-well tissue culture plates). Cells were induced for 24 hwith solvent (ethanol), PMA
(10 ng/ml), PMA plus agonist (106 M), or PMA plus CpdA (105 M) (agonist mode) or with PMA, PMA plus agonist (106 M), PMA plus agonist (106 M) and
antagonist (106 M), or PMA plus agonist (106 M) and CpdA (105 M) (antagonist mode) 24 h after replating. Luciferase values were normalized with protein
concentration and values plotted as fold-induction S.E. (error bars) relative to average solvent (agonistmode) or as percentage of PMA induction (antagonist
mode). Statistical analysis was done to compare values in the presence of test compounds relative to PMA induction (*, p 0.05; **, p 0.01; ***, p 0.00) for
agonist mode or PMA plus corresponding agonist induction ($, p 0.05; $$, p 0.01; $$$, p 0.001) for antagonist mode using one-way analysis of variance
with Dunnett’s multiple comparisons test as post test. Agonists used: Dex for GR; aldosterone for MR; R5020 for PR; DHT for AR; E2 for ER. Antagonists used:
RU486 for GR; spironolactone for MR; RU486 for PR; hydroxyflutamide for AR; ICI 182,780 for ER.
rather than PMA as the pro-inflam-
matory stimulus,which showed that
CpdA acted only via GR (6).
Further examination of the ste-
roid receptor specificity of CpdA in
transrepression, however, indicates
that within the context of the Cbg
minimal promoter and at the CBG
protein level, CpdA displays a much
greater steroid receptor specificity
in only transrepressing CBG via the
GR, and not viaMR, PR,AR, and ER.
In contrast to this, we found that the
AR antagonist activity displayed by
CpdA on a GRE-containing syn-
thetic reporter in COS-1 cells was
mimicked in BWTG3 cells for
expressed AR-mediated regulation
of endogenous TAT activity. It has
been suggested that the flanking
sequences around GREs may play
an important role in receptor speci-
ficity (61) and that individual GREs
retain specific “architectural sig-
natures” that includes distinct GR-
binding sites as well as binding
motifs for other transcription fac-
tors (62). Thus by investigating only
isolated transcription binding sites
the role of these flanking sequences
that may contribute to the compos-
ite elements (63) enriched for
motives to GR as well as other tran-
scription factorsmay be overlooked.
We suggest then that the Cbg pro-
moter may contain such addi-
tional motifs that contribute to
the steroid receptor specificity of
CpdA. In addition, our results sug-
gest that the steroid receptor spec-
ificity of the anti-inflammatory
action of CpdA in transrepressing
pro-inflammatory cytokines may
be co-determined by cell type,
pro-inflammatory stimulus, pro-
moter context, as well as cell-spe-
cific regulation of hormone recep-
tor expression/activities.
In summary, our results suggest
that the ability of CpdA to elicit a
conformational change in the GR,
which abrogates dimerization, is
sufficient to explain the observed
dissociation between transactiva-
tion and transrepression. However,
our results do not exclude the possi-
bility that additional mechanisms,
such as an impaired ability of CpdA-
FIGURE 8. CpdA shows greater steroid receptor specificity in context of the Cbg promoter construct and
at the CBG, but not TAT, protein level. A, steroid receptor specificity of transrepression of the transiently
transfected rat CBG295Luc promoter reporter construct via GR, MR, PR, AR, or ER. COS-1 cells (2  106 cells/
plate in 10-cm tissue culture dishes) were transiently transfected with 9 g of CBG295Luc and 3 ng of pRS-
hGR, pRS-hMR, pSG5hPRB, pSVARo, or pcDNA3-ER as indicated. Twenty-four h after transfection cells were
replated (5  104 cells/well in 24-well tissue culture plates) in medium with 10% dextran-coated charcoal-
stripped FCS and 1% antibiotics, except for assays investigating ER activity, where phenol red-free medium
with 10% dextran-coated charcoal-stripped FCS and 1% antibiotics was used. Cells were induced, in DMEM
without supplements except in assays investigating ER activity, where phenol red-free medium with 10%
dextran-coated charcoal-stripped FCS and 1% antibiotics was used, for 24 h with solvent (ethanol), agonist
(106 M), or CpdA (105 M) 24 h after replating. Luciferase values were normalized with protein concentration
and values plotted as fold-induction S.E. (error bars) relative to average control. Statistical analysis was done
for each steroid receptor to compare values in the presence of test compounds relative to the corresponding
control using two-way analysis of variance followed by Bonferroni post tests (*, p 0.05; **, p 0.01; ***, p
0.001). B, transrepression of CBGprotein levels by steroid receptor ligands via endogenous steroid receptors in
BWTG3 cells. BWTG3 cells (2.5 105 cells/well in 6-well tissue culture plates) were induced 24 h after plating
with solvent (ethanol), steroid receptor agonist (106 M) or CpdA (105 M) inmediumwith 10%dextran-coated
charcoal-stripped FCS and antibiotics except for assays investigating ER activity, where phenol red-free
mediumwith 10% dextran-coated charcoal-stripped FCS and antibiotics was used. After 24 h cells were lysed,
and lysates were separated on a SDS-PAGE gel and transferred to a Hybond-ECL nitrocellulose membrane,
which was probed for CBG (S1000–76Z) and actin (sc-1616). Proteins were visualized using ECL peroxidase-
labeled anti-goat antibody and ECL Western blotting detection reagents on Hyperfilm. For determination of
CBG levels Hyperfilm bands of CBG and actin were quantified and results expressed as intensity of the CBG
band relative to actin band S.E. (error bars). Statistical analysis was done to compare values in the presence
of test compounds relative to the corresponding control using one-way analysis of variance followed by
Dunnett’smultiple comparisonspost test (*,p0.05; **,p0.01; ***,p0,001). Table inset: whole cell binding
was done in BWTG3 cells to determine endogenous steroid receptor levels by incubating BWTG3 cells with
[3H]Dex for GR, [3H]E2 for ER, [
3H]R5020 for PR, [3H]mibolerone for AR, or [3H]aldosterone for MR. Cognate
unlabeled ligands were added in 1000-fold excess. Specific binding is presented in femtomole/mg of protein.
C, transactivation of TAT activity in BWTG3 cells transfectedwith AR. BWTG3 cells (2.5 105 cells/well in 6-well
tissue culture plates) were transiently transfected with 150 ng of pSVARo and induced 24 h after transfection
with solvent (ethanol), DHT, AR agonist (106 M), DHT, AR agonist (106 M) plus hydroxyflutamide, AR antago-
nist (106 M), or DHT, AR agonist (106 M) plus CpdA (105 M) in medium with 10% dextran-coated charcoal-
stripped FCS and antibiotics. Cell lysate was prepared and assayed for TAT activity S.E. (error bars) 4 h after
induction. Statistical analysis was done to compare values in the presence of test compounds relative to
control using one-way analysis of variance followed by Dunnett’s multiple comparisons post test (*, p 0.05).
Agonists used: Dex for GR; aldosterone (Ald) for MR; R5020 for PR; DHT for AR; E2 for ER. Antagonists used:
hydroxyflutamide for AR.
liganded GR to bind to DNA, also play a role. Transrepression
models shown to require DNA binding but not dimerization,
such as shown for the keratin genes (64), would be useful to
investigate this possibility. Investigation of genes shown to
transactivate via tethering mechanisms, where no DNA bind-
ing or dimerization is required, such as for the -casein gene
where GR was shown to transactivate through tethering to sig-
nal transducers and activators of transcription (STAT) 5 (65),
could also be useful to shed light on this aspect. It may be that
CpdA elicits a conformational change in the GR that results in
differential recruitment of cofactors as have been shown for the
dissociated GC, AL-438 (38). In support of this hypothesis, it
has previously been shown that, unlikeDex, CpdAbound to the
GRdoes not recruitGRIP-1, SRC-1A,NcoR, or SMRT, suggest-
ing that CpdA, acting via the GR, may recruit different cofac-
tors as compared with Dex (32).
Altogether, CpdA represents a novel, non-steroidal, dissoci-
ated GR modulator, which abrogates GR dimerization. This
makesCpdA a very attractive candidate to investigate for future
therapeutic applications (28, 51, 66). However, its use as a GR
ligand that can shed light on the fundamental mechanisms
underlying the regulation of gene expression by the GR, specif-
ically the role of GR dimerization, should not be underesti-
mated. Within this context the decrease in maximal nuclear
import and increase in nuclear export rate for CpdA-bound
wtGR, as for Dex-bound GRdim, as compared with Dex-bound
wtGR, shown in the current paper, suggests that loss of GR
dimerization results in a GR species that exits the nucleus at a
significantly faster rate and thatGRdimerization contributes to
the amount ofGRpresent in the nucleus upon ligand activation.
Previous work has suggested that the hinge region of the GR
contains a solution dimerization domain (23) involved in cyto-
solic dimerization of the liganded GR, a nuclear localization
signal, NL1 (40), that mediates liganded and unliganded GR
nuclear location, and a nuclear retention signal that actively
retains the GR in the nucleus (67). Loss of NL1 and nuclear
retention signal results in increased nuclear export and reduced
nuclear occupancy, which closely resembles the effect found
with CpdA and GRdim in the current study. However, the
regions involved do not overlap (hinge region: amino acids
505–547 and GRdim mutation at amino acid 458 in the ligand
binding domain) suggesting a potentially novel insight
regarding additional factors that influence nuclear retention
of the GR.
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